SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
Authors:
- María Martínez-GarcíaMMMaría Martínez-García
- Sonia Servitja TormoSTSonia Servitja Tormo
- Noelia Vilariño QuintelaNQNoelia Vilariño Quintela
- Ana Arance FernándezAFAna Arance Fernández
- Alfonso Berrocal JaimeAJAlfonso Berrocal Jaime
- Blanca Cantos Sánchez de IbargüenBIBlanca Cantos Sánchez de Ibargüen
- Sonia Del Barco BerrónSBSonia Del Barco Berrón
- Rosario García CampeloRCRosario García Campelo
- Regina Gironés SarrióRSRegina Gironés Sarrió
- Juan Manuel Sepúlveda-SánchezJSJuan Manuel Sepúlveda-Sánchez
Open Access
- 8 March 2022
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 24 (4) , 703-711
Abstract
Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent increase in incidence of BMs is due to several factors including better diagnostic assessments and the development of improved systemic therapies that have lower activity on the CNS. However, newer systemic therapies are being developed that can cross the blood–brain barrier giving us additional tools to treat BMs. The guidelines presented here focus on the efficacy of new targeted systemic therapies and immunotherapies on CNS BMs from breast, melanoma, and lung cancers.Keywords
This publication has 71 references indexed in Scilit:
- Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutationLung Cancer, 2015
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialThe Lancet, 2015
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancersLung Cancer, 2015
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR MutationsClinical Cancer Research, 2012
- Comparison of Different Treatment Approaches for One to Two Brain Metastases in Elderly PatientsStrahlentherapie und Onkologie, 2008
- Capecitabine Therapy of Central Nervous System Metastases from Breast CancerJournal of Neuro-Oncology, 2007
- Irradiation of rat brain reduces P-glycoprotein expression and functionBritish Journal of Cancer, 2007
- Reviewing the definition of “elderly”Geriatrics & Gerontology International, 2006
- Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects?Supportive Care in Cancer, 2002